Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

127.10 +2.80 (+2.25%)

Streaming Delayed Price Updated: 12:17 PM EDT, Jun 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

75 76 Next >

If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today ↗

April 03, 2024

Via Benzinga

Biotech Sector Nears Breakout: Will it Outperform in Q2?

April 03, 2024

The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains

Via MarketBeat

Topics ETFs

5 Healthcare Stocks to Buy for 2024 ↗

April 02, 2024

Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.

Via InvestorPlace

Topics Artificial Intelligence

Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst ↗

April 01, 2024

BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets.

Via Benzinga

10 Big-Name Stocks Near 52 Week Lows: Are They A Buy? ↗

March 29, 2024

Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week...

Via Talk Markets

Analyzing NASDAQ:GILD's Dividend Potential. ↗

March 26, 2024

Is GILEAD SCIENCES INC (NASDAQ:GILD) a Good Fit for Dividend Investing?

Via Chartmill

If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,100 Today ↗

March 11, 2024

Via Benzinga

Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why ↗

March 28, 2024

Xilio Therapeutics soars with exclusive license pact with Gilead Sciences to advance XTX301, a Phase 1 tumor-activated IL-12 program. $43.5 million upfront, $604 million potential payments, and tiered...

Via Benzinga

Why Is Xilio Therapeutics (XLO) Stock up 168% Today? ↗

March 28, 2024

Xilio Therapeutics stock is heading higher on Thursday with heavy trading of XLO shares after announcing a deal with Gilead.

Via InvestorPlace

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

March 28, 2024

From Gilead Sciences, Inc.

Via Business Wire

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

March 28, 2024

From Gilead Sciences, Inc.

Via Business Wire

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

March 28, 2024

From Xilio Therapeutics, Inc.; Gilead Sciences, Inc.

Via GlobeNewswire

7 Value Stocks to Buy at a 52-Week Low in March ↗

March 28, 2024

These seven value stocks to buy all trade at low valuations, and have the potential to make big recoveries.

Via InvestorPlace

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields ↗

March 27, 2024

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich ↗

March 25, 2024

Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.

Via InvestorPlace

2 Top Dividend Stocks to Buy Hand Over Fist ↗

March 17, 2024

Every company faces headwinds eventually. The top ones know how to bounce back.

Via The Motley Fool

10 Big-Name Stocks Near 52-Week Lows: Are They A Buy? ↗

March 16, 2024

Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week...

Via Talk Markets

Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production ↗

March 15, 2024

Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a...

Via Benzinga

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

March 11, 2024

From Gilead Sciences, Inc.

Via Business Wire

3 Dividend Stocks to Buy Hand Over Fist in March ↗

March 10, 2024

Income investors might want to load up on these great dividend stocks.

Via The Motley Fool

The AI Race Gets Litigious ↗

March 09, 2024

We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer ↗

March 08, 2024

FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at...

Via Benzinga

Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗

March 07, 2024

Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.

Via Benzinga

Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy ↗

March 06, 2024

Gilead Sciences and Merck's Phase 2 study on islatravir and lenacapavir combo for HIV shows 94.2% viral suppression at 24 weeks. Potent antiviral activity revealed.

Via Benzinga

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

March 06, 2024

From Gilead Sciences, Inc.

Via Business Wire

Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers ↗

March 06, 2024

Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...

Via Benzinga

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

March 06, 2024

From Gilead Sciences, Inc.

Via Business Wire

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

March 06, 2024

From Gilead Sciences, Inc.

Via Business Wire

New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19

March 05, 2024

From Gilead Sciences, Inc.

Via Business Wire

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

March 05, 2024

From Gilead Sciences, Inc.

Via Business Wire

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.